# A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

Source: https://onco.cc/trials/nct06105619/  
OnCo record `nct06105619` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Vebreltinib run by Beijing Pearl Biotechnology Limited Liability Company, active.

## Summary

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). is a phase 2/3 interventional study registered as NCT06105619 by Beijing Pearl Biotechnology Limited Liability Company, with 84 participants enrolled, started 2018-10-08. Conditions listed: Glioblastoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06105619
- Phase: 2/3
- Setting: A Randomized, Controlled, Open, Multicenter, Phase II/III Clinical Study to Evaluate the Safety and Efficacy of Vebreltinib Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
- Sponsor: Beijing Pearl Biotechnology Limited Liability Company
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT06105619: https://clinicaltrials.gov/study/NCT06105619

## Connected records

- drugs: [Vebreltinib](https://onco.cc/drugs/vebreltinib/)

---
JSON: https://onco.cc/api/v1/entities/nct06105619.json